TY - JOUR
T1 - Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome
AU - Streng, Bianca M.M.
AU - Bont, Marin
AU - Delemarre, Eveline M.
AU - Binnendijk, Rob S.
AU - Smit, Gaby
AU - den Hartog, Gerco
AU - Coppus, Antonia M.W.
AU - de Vries, Esther
AU - Weijerman, Michel E.
AU - Lamberts, Regina
AU - de Graaf, Gert
AU - van der Klis, Fiona R.
AU - Vidarsson, Gestur
AU - Rave, Neele
AU - Bont, Louis J.
AU - Wildenbeest, Joanne G.
N1 - Funding Information:
This work was supported by ZonMw, The Netherlands Organization for Health Research and Development (10430072010004). Funding to pay the Open Access publication charges for this article was provided by the Dutch Universities and Academic Hospitals (VSNU).
Publisher Copyright:
© 2022 The Author(s) 2022.
PY - 2022/8/15
Y1 - 2022/8/15
N2 - The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.
AB - The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1-specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]-1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.
KW - COVID-19 vaccination
KW - Down syndrome
KW - SARS-CoV-2
KW - antibody response
UR - https://www.scopus.com/pages/publications/85137153699
U2 - 10.1093/infdis/jiac235
DO - 10.1093/infdis/jiac235
M3 - Article
C2 - 35748853
AN - SCOPUS:85137153699
SN - 0022-1899
VL - 226
SP - 673
EP - 677
JO - The Journal of infectious diseases
JF - The Journal of infectious diseases
IS - 4
ER -